Abstract
Amyloid β-peptide (Aβ), which plays a central role in Alzheimer Disease, is generated by presenilin-dependent and presenilin-independent γ-secretase cleavages of β-amyloid precursor protein (βAPP). We report that the presenilins (PS1 and PS2) also regulate p53-associated cell death Thus, we established that PS deficiency, catalytically inactive PS mutants, γ-secretase inhibitors and βAPP or APLP2 depletion reduced the expression and activity of p53, and lowered the transactivation of its promoter and mRNA levels. p53 expression was also reduced in the brains or βAPP-deficient mice or in brains where both PS had been invalidated by double conditional knock out. AICDC59 and AICDC50, the γ- and η- secretase-derived C-terminal fragments of βAPP, respectively, trigger the activation of caspase-3, p53-dependent cell death, and increase p53 activity and mRNA. Finally, HEK293 cells expressing PS1 harboring familial AD (FAD) mutations or FAD-affected brains, all display enhanced p53 activity and p53 expression. Our studies demonstrate that AICDs control p53 at a transcriptional level, in vitro and in vivo and unravel a still unknown function for presenilins.
Keywords: Presenilins, nicastrin, caspase-3, p53 expression, transcriptional activation
Current Alzheimer Research
Title: The γ /η-Secretase-Derived APP Intracellular Domain Fragments Regulate p53
Volume: 4 Issue: 4
Author(s): Frederic Checler, Claire Sunyach, Raphaelle Pardossi-Piquard, Jean Sevalle, Bruno Vincent, Toshitaka Kawarai, Nadege Girardot, Peter St George-Hyslop and Cristine Alves da Costa
Affiliation:
Keywords: Presenilins, nicastrin, caspase-3, p53 expression, transcriptional activation
Abstract: Amyloid β-peptide (Aβ), which plays a central role in Alzheimer Disease, is generated by presenilin-dependent and presenilin-independent γ-secretase cleavages of β-amyloid precursor protein (βAPP). We report that the presenilins (PS1 and PS2) also regulate p53-associated cell death Thus, we established that PS deficiency, catalytically inactive PS mutants, γ-secretase inhibitors and βAPP or APLP2 depletion reduced the expression and activity of p53, and lowered the transactivation of its promoter and mRNA levels. p53 expression was also reduced in the brains or βAPP-deficient mice or in brains where both PS had been invalidated by double conditional knock out. AICDC59 and AICDC50, the γ- and η- secretase-derived C-terminal fragments of βAPP, respectively, trigger the activation of caspase-3, p53-dependent cell death, and increase p53 activity and mRNA. Finally, HEK293 cells expressing PS1 harboring familial AD (FAD) mutations or FAD-affected brains, all display enhanced p53 activity and p53 expression. Our studies demonstrate that AICDs control p53 at a transcriptional level, in vitro and in vivo and unravel a still unknown function for presenilins.
Export Options
About this article
Cite this article as:
Checler Frederic, Sunyach Claire, Pardossi-Piquard Raphaelle, Sevalle Jean, Vincent Bruno, Kawarai Toshitaka, Girardot Nadege, George-Hyslop Peter St and da Costa Alves Cristine, The γ /η-Secretase-Derived APP Intracellular Domain Fragments Regulate p53, Current Alzheimer Research 2007; 4(4) . https://dx.doi.org/10.2174/156720507781788945
DOI https://dx.doi.org/10.2174/156720507781788945 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Nutritional Supplements Modulating Metabolic Syndrome Risk Factors and the Prevention of Cardiovascular Disease
Current Nutrition & Food Science Study of the Effects of L-tryptophane Nanoparticles on Motor Behavior in Alzheimer's Experimental Models
CNS & Neurological Disorders - Drug Targets Acknowledgements to Reviewers:
Current Alzheimer Research Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Chemoprevention
Current Drug Targets Aliphatic and Aromatic Oxidations, Epoxidation and S-Oxidation of Prodrugs that Yield Active Drug Metabolites
Current Medicinal Chemistry Synthesis of Novel 4-Aryl-1,2,3,4-tetrahydroisoquinolines as Probes for Dopamine Receptor Ligands
Medicinal Chemistry Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) Cytokines as a Precipitant of Depressive Illness: Animal and Human Studies
Current Pharmaceutical Design The Association Between Alcohol Use and the Progression of Alzheimer’s Disease
Current Alzheimer Research Invertebrate Models of Dystonia
Current Neuropharmacology ISATIN: New Hope Against Convulsion
Central Nervous System Agents in Medicinal Chemistry Considering a Potential Role of Linalool as a Mood Stabilizer for Bipolar Disorder
Current Pharmaceutical Design Participation of the Cannabinoid System in the Regulation of Emotional- Like Behaviour
Current Pharmaceutical Design Targeting Toll-like Receptors in Autoimmunity
Current Drug Targets A Pharmacophore Model Specific to Active Site of CYP1A2 with a Novel Molecular Modeling Explorer and CoMFA
Medicinal Chemistry Obstructive Sleep Apnoea Syndrome and Diabetes. Fortuitous Association or Interaction?
Current Diabetes Reviews Clinical Application of Ghrelin
Current Pharmaceutical Design Ligand Docking and Structure-based Virtual Screening in Drug Discovery
Current Topics in Medicinal Chemistry Pharmacological Approaches in the Treatment of Atrial Fibrillation
Current Medicinal Chemistry Editorial [Hot Topic: Cannabinoid Receptors Ligands (Guest Editor: Gabriele Murineddu)]
Recent Patents on CNS Drug Discovery (Discontinued)